Vanguard Capital Management
INTS icon

Vanguard Capital Management’s Intensity Therapeutics INTS Stock Holding History

Vanguard Capital Management’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Buy
26,569
+9,728
+58% +$45.7K ﹤0.01% 3871
2026
Q1 		$99K Buy
+16,841
New +$138K ﹤0.01% 3866

Other funds holding INTS

KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Vanguard Capital Management's INTS Position: Q2 2026 in Review

Vanguard Capital Management increased its Intensity Therapeutics (INTS) stake by 58% in Q2 2026, buying an estimated $45.7K and bringing the position to 26,569 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #3871.

Vanguard Capital Management first reported a position in INTS in Q1 2026 and has held it in 2 quarters since. 17 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • Vanguard Capital Management held 26,569 shares of Intensity Therapeutics worth $109K as of Q2 2026.
  • Vanguard Capital Management bought 9,728 Intensity Therapeutics shares in Q2 2026, an estimated $45.7K.
  • Intensity Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3871 holding.
  • Vanguard Capital Management first reported a position in Intensity Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 17 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.